|Videos|January 18, 2023

Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Author(s)Stephen J. Freedland, MD

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

Episodes in this series

EP. 1 Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP. 1 Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 3 Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP. 3 Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP. 4 The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

EP. 4 The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

EP. 5 Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

EP. 5 Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Why methodology matters in real-world evidence studies

ByMartin Schoen, MD, PhD

September 3rd 2026

Prostate Cancer Awareness Month: Prostate cancer screening in 2026

ByShiv B. Patel, MD,Hannah Clarke

September 3rd 2026

Enrollment goal met in phase 3 study of 68Ga-PSMA-PET in pre-biopsy setting

ByHannah Clarke

September 2nd 2026

Cardiovascular referral improves risk-factor control in prostate cancer, but not clinical events

ByHannah Clarke

September 2nd 2026

Martin Schoen, MD, PhD, on selecting among ARPIs in prostate cancer

ByMartin Schoen, MD, PhD

September 1st 2026

Latest CME

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Prostate Cancer Awareness Month: Prostate cancer screening in 2026

Meeting men where they are: A urologist's case for community outreach

Pearls & Perspectives: Sexual Wellness and Premature Ejaculation, With Chris Harris, MBA

FDA reports increased demand, supply efforts for estradiol transdermal patches

Enrollment goal met in phase 3 study of 68Ga-PSMA-PET in pre-biopsy setting